TWST Stock Analysis
TW
Uncovered
Twist Bioscience Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 989 full-time employees. The company went IPO on 2018-10-31. The firm has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The firm utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. The company consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.